Compare Repligen Corporation Common Stock (RGEN) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs STMicroelectronics NV — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while STMicroelectronics NV trades at $44.71 (market cap $43.15B). The key difference: STMicroelectronics NV is far larger — about 3.8× Repligen Corporation Common Stock's market cap, and STMicroelectronics NV pays a 0.77% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and STMicroelectronics NV for 65 Days on average.
| RGEN | STM | |
|---|---|---|
Market Cap | $11.31B | $43.15B |
Volume | 1,216,919 | 14,115,128 |
Sector | Health | Technology |
52-Week High | $194.57 | $79.91 |
52-Week Low | $102.87 | $21.20 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $11.20B | $40.67B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
STM trades at $49.57, down 1.8% today, with a bearish technical signal. The stock shows mixed fundamentals with declining revenue from $17.3B in 2023 to $11.8B in 2025 and negative net income margin of -0.39%. However, analyst consensus remains positive with a $77.31 price target and 52% buy ratings, supported by strong AI data-center revenue projections exceeding $2B by 2027 and improving cash flow trends.
The outlook suggests potential upside from AI and automotive demand, but near-term risks include margin pressure from facility transitions and volatile earnings. Investors face a trade-off between high valuation multiples and growth catalysts in semiconductor markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
